RESEARCH PRESENTATIONS & ABSTRACTS

RESEARCH PRESENTATIONS & ABSTRACTS

 Cohen STaR ICAAC 2014 thumbnail Cohen C, Wohl D, Cavassini M, et al. STaR study: Single-tablet regimen rilpivirine/emtricitabine/tenofovir DF is non-inferior compared to
efavirenz/emtricitabine/tenofovir DF and improves patient reported outcomes through week 96. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-September 9, 2014; Washington, DC.
 Cohen-AIDS-2014-PPT Cohen C. Regimen Selection in HIV: Considering New Options to Optimize Outcomes / ART Initiation: PrEP and Treatment-naïve Patients.  PowerPoint SUSA03. Presented at: 20th International AIDS Conference; Jul 20-24, 2014; Melbourne, Australia.
abstract 1presentation 1 Shalit P, Cohen CJ, Mills A, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF demonstrates comparable efficacy to efavirenz/emtricitabine/tenofovir DF in subjects with adherence <95%. Presented at: 7th International IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.
poster 2abstract 2presentation 2 Cohen CJ. STaR study: single tablet regimen rilpivirine/emtricitabine/tenofovir DF has non-inferior efficacy compared to efavirenz/emtricitabine/tenofovir DF and improves patient reported outcomes. Presented at: 7th International IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.
poster 3abstract 3 Cohen C, Green J, Olivet H, Khanlou H, et al. A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r vs. RAL BID + ATV BID. Presented at: Eleventh International Congress on Drug Therapy in HIV Infection; November 11-15, 2012; Glasgow, UK.
abstract 4 A Zolopa, J Gallant, C Cohen, P Sax, E Dejesus, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1-infected patients. Presented at: Eleventh International Congress on Drug Therapy in HIV Infection; November 11-15, 2012; Glasgow, UK.
abstract 5 Cohen CJ, Wohl D, Arribas J, Henry K, et al. STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults; November 11-15, 2012; Glasgow, UK.
poster 6abstract 6 Cohen CJ, Davis K, Meyers J. Association of partial adherence (PA) to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population. Presented at: Eleventh International Congress on Drug Therapy in HIV Infection; November 11-15, 2012; Glasgow, UK.
poster 7abstract 7 Cohen CJ, Davis K, Meyers J. Association between selective adherence to antiretroviral therapy and hospitalization risk in an HIV population. Presented at: Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA.
poster & abstract 8 Behrens G, Rijnders B, Nelson M, Orkin C, Cohen CJ, et al. Efficacy and safety outcomes for rilpivirine (RPV) versus efavirenz (EFV) plus emtricitabine/tenofovir DF (FTC/TDF) in treatment-naïve, HIV-1-positive adults with baseline viral load ≤ 100,000 copies/mL – pooled 48-week ECHO and THRIVE analysis. Presented at: Nineteenth International AIDS Conference; July 22–27, 2012; Washington, DC.
abstract 9 Holman J, Schneider K, Cranston K, Fukuda HD, Goldrosen M. HIV stigma among people living with HIV in Massachusetts and southern New Hampshire, 2009. Presented at: Nineteenth International AIDS Conference; July 22–27, 2012; Washington, DC.
abstract 10 Sax P, De Jesus E, Mills A, Zolopa A, Cohen CJ, et al. Analysis of efficacy by baseline HIV RNA: week 48 results from a phase 3 study of elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to efavirenz/emtricitabine/tenofovir DF in treatment-naïve HIV-1-positive subjects. Presented at: Nineteenth International AIDS Conference; July 22–27, 2012; Washington, DC.
presentation 11poster 11 Cohen CJ, Molina J, Jayaweera D, et al. Relationship between combination of baseline viral load and CD4 cell count, and Week 48 or 96 responses to rilpivirine (RPV) or efavirenz (EFV) in treatment-naïve HIV-1-infected adults: pooled analysis from the Phase III ECHO and THRIVE trials. Presented at: The Nineteenth Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA.
abstract1 Sax P, DeJesus E, Mills A, Zolopa A, Cohen CJ, et al. The efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (“Quad”) compared to efavirenz/emtricitabine/tenofovir DF in treatment naïve HIV-1 infected subjects: Primary results of Study GS-US-236-0102. Presented at: The Nineteenth Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA.
poster 12abstract 12 Cohen CJ, Davis K, Meyers J. Association between daily antiretroviral pill burden and hospitalization risk in a medicaid population with HIV. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-30, 2011; Chicago, IL.
poster 13 Cohen CJ, Molina J-M, Cahn P, Clotet B, Fourie J, Grinsztejn B, Hao W, Johnson M, Saag M, Supparatpinyo K, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K. Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomized, Phase III trials comparing rilpivirine (RPV, TMC278) vs. efavirenz (EFV) in treatment-naive, HIV-1-infected adults. Presented at: The VI International AIDS Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2011; Rome, Italy.
abstract 13presentation 13poster 13 Skiest D, Cohen CJ, Khanlou H, DeJesus E, Vanig T, Tribble M, Petroll A, Olivet H, Garb J, Mounzer K. Randomized comparison of darunavir/r versus atazanavir/r on serum lipids in HIV-infected persons on fully suppressive lopinavir/r or fosamprenavir/r with high serum triglycerides. Lopinavir/r or fosamprenavir/r switch to atazanavir/r or darunavir/r (LARD). Presented at: Eighteenth Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA.
abstract 14presentation 14 Cohen CJ, Molina J-M, Cahn P, Clotet B, Fourie J, Grinsztejn B, Hao W, Johnson M, Saag M, Supparatpinyo K, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients. Presented at: The XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria.
presentation 16 Cohen CJ, Shamblaw D, Ruane P, Elion R, DeJesus E, Liu H, Zhong L, Warren D, Kearney B, Chuck S. Single-tablet, fixed-dose regimen of elvitegravir/emtricitabine/tenofovir disoproxil rumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. Presented at: Seventeenth Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA.
presentation 17 Palleja S, Cohen CJ, Gathe J, Thompson M, DeJesus E, Brinson C, Elion R, Galindez J, Martin E, Sapirstein J. Safety and efficacy of TBR 652, a CCR5 antagonist, in HIV-1-infected, ART-experienced, CCR5 antagonist-naïve patients. Presented at: Seventeenth Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA.
abstract 17 Sheble-Hall S, Jackson-Pope L, Green J, Jensen J, McLaughlin K. Community based HIV/AIDS clinical research: implications for the research nurse in a changing business model. Presented at: Twenty-second Annual Conference of the Association of Nurses in AIDS Care; November 18-22, 2009; Jacksonville, FL.
abstract 18poster 18 Green J. A novel and focused approach to Community Advisory Board (CAB) development and maintenance builds community members’ capacity to educate consumers about HIV clinical research, resources, and health maintenance. Presented at: Twenty-second Annual Conference of the Association of Nurses in AIDS Care; November 18-22, 2009; Jacksonville, FL.
abstract 20presentation 20 Cohen CJ, Liporace R, DeJesus E, Khanlou H, Vanig T, Schrager H, Habel A, Colsen A, Jensen J, Garb J. Use of twice daily darunavir as a substitution for dual boosted PIs in virologically suppressed patients: primary endpoint results of a pilot randomized clinical trial. Presented at: Twelfth European AIDS Conference; November 11-14, 2009; Cologne, Germany.
bravo1 Skiest D, Cohen CJ, Barker D, Gottlieb M, Mounzer K, Bellman P, Dejesus E, Khanlou H, Rashbaum B, Hsiao CB, Ruane P, Abriola K, Bellos N, Ward D, Lalezari J, Santiago F, Garb J, Habel A. Raltegravir without a protease inhibitor is highly efficacious in heavily pre-treated individuals. Presented at: Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2009; Cape Town, South Africa.
foto1 Cohen CJ, Colson A, Pierone G, Dejesus E, Kinder F, Elion R, Skiest D, Habel A, Jensen J, Garb J, Schrager H, Back D. The FOTO study: The 48 week extension to assess durability of the strategy of taking efavirenz, tenofovir and emtricitabine Five days On, Two days Off (FOTO) each week in virologically suppressed patients. Presented at: Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2009; Cape Town, South Africa.
abstract 22presentation 22 Cohen CJ, Colson A, Pierone G. The FOTO study: Twenty-Four week results support the safety of a two day break on efavirenz-based antiretroviral therapy. Presented at: Ninth International Congress on Drug Therapy in HIV Infection; November 8-13, 2008; Glasgow, UK.
Not Available Online Jackson-Pope L, Hussey S, Marston J, Colson A, Cohen CJ. Shifting gears in site management: transforming a clinical trial site into an organization which coordinates multi-site investigator-initiated studies on novel treatment strategies for HIV. Presented at: The Society of Clinical Research Associates, Inc; September 25-28, 2008; Vancouver, BC, Canada.
presentation 23 Towner W, Haigney Z, Sension MG, Wohlfeiler M, Gathe J, Appelbaum JS, et al. Efficacy, safety, and tolerability of etravirine with and without darunavir and/or raltegravir in treatment-experienced patients: Preliminary analysis of TMC125-C214 Early Access Program (EAP) in the US. Presented at: The XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
Not Available Online Boyle BA, Cohen CJ, et al. Update on Antiretroviral Therapy: The 15th CROI. The AIDS Reader. 18(5):273-278. May 2008. A Cliggott Publication. PMID: 18589484.
Not Available Online DeJesus E, Cohen CJ, Elion R, et al. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137). Poster TUPE8032. 4th International AIDS Society (IAS) Conference on Pathogenesis, Treatment and Prevention incorporating the 19th ASHM Conference; Jul 22-25, 2007; Sydney, Australia.
abstract2 D Skiest, Krambrink A, Su Z, Robertson K, Havlir D, Margolis D, and the ACTG 5170 team. Patients reported symptoms improve following prolonged treatment interruption: ACTG 5170 quality of life results. Presented at: The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 22-25, 2007; Sydney, Australia.
sd Boyle BA, Cohen CJ. Editorial comment: Impact of darunavir for salvage therapy. The AIDS Reader. 17(3):160-161. Mar 2007. A Cliggott Publication. PMID: 17396333.
Not Available Online Boyle BA, Cohen CJ, et al. XVI International AIDS Conference: Part 2. The AIDS Reader. 16(11):581-584. Nov 2006. A Cliggott Publication. PMID: 17152645.
Not Available Online Cohen CJ, DeJesus E, Campo R, et al. Simplification from protease inhibitor (PI) to efavirenz (EFV) based HAART in virologically suppressed HIV-infected subjects. 8th International Congress on Drug Therapy in HIV Infection; Nov 12-16, 2006; Glasgow, Scotland.
poster 24 Colson AE, Cohen CJ, Stevens R, et al. The impact of changing tenofovir and lamivudine to co-formulated tenofovir and emtricitabine (Truvada) in adults with virologic suppression. Presented at: The 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, UK.
  Cohen CJ. Successful HIV Treatment: Lessons Learned. Journal of Managed Care Pharmacy. 12(7 Suppl B):S6-11. Sep 2006. PMID: 16984222.
abstract3 Colson AE, Cohen CJ, McLaughlin K, Habel A, Hellinger JA. The StARS study of once daily Atazanavir, low-dose Ritonavir, and Saquinavir: Impact of changing LPVr to ATVr in combination with SQV. Presented at: The 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; September, 2006; San Francisco, California.
abstract 25 Horne R, Cooper V,Tsoukas C, Katlama C, Cohen CJ, et al. Injectable therapy in HIV: The role of physician and patient attitudes. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada.
abstract 26 Cohen CJ, Barbato L, Shapira A, et al. Exploratory analysis of a double-blind randomized trial of dronabinol for nausea in HIV/AIDS patients receiving highly active antiretroviral therapy (HAART). Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada.
abstract 27 Penner J, Marima R, Olubwayo C, Onunga S, Bukusi E, Cohen CJ. As little as one peer educator can increase acceptance of HIV testing in a PMTCT programme. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada.
abstract 28 Montandon M, Bukusi E, Boland B, Sharma A, Agot K, Cohen CJ. Adolescent girls’ perspectives on research of female-controlled HIV prevention methods in Kenya. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada.
abstract4 Cohen CJ, Steinhart C, Ward D, et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada.
abstract 29 Molina JM, Cohen CJ, Katlama C, et al. TMC114/r in treatment-experienced HIV patients in power 3: 24-week efficacy and safety analysis. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada.
abstract 30 Grossman H, Cohen CJ, Nadler J, et al. Prediction of clinical benefits of TMC125 from treatment effects on CD4 counts and HIV RNA. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada.
abstract 31 Green J, et al. Success in development and maintenance of a diverse community advisory board (CAB) supports the mission of broadening access to clinical trials for underserved populations at a multi-site, not for profit, community-based research center – Community Research Initiative. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada.
abstracts 32 Cohen CJ, Steinhart CR, Ward DJ, Ruane PJ, Peeters M, Woodfall B. 48-week durable efficacy and safety results of TMC125 in HIV patients with NNRTI and PI resistance: Study TMC125-C223. Presented at: Program and Abstracts of the 12th Annual Conference of the British HIV Association; March 29-April 1, 2006; Brighton, United Kingdom.
 Not Available Online Skiest D, Havlir D, Coombs R, et al. Predictors of HIV disease progression in patients who stop ART with CD4 cell counts greater than 350 cells per mm3. Presented at: The 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO.
 Not Available Online DeJesus E, Berger D, Markowitz M, Cohen CJ, et al. The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naïve and experienced patients. Presented at: The 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO.
poster 33 Berger DS, Bellos N, Farthing C, Stryker R, Colson AE, et al. TMC114/r in 3 class-experienced patients: 24-week primary safety analysis of the power 2 study (C202). Presented at: The 45th ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC.
poster 34 Cohen CJ, Elion R, DeJesus E, et al, for the COL40263 study team. Week 48 analysis of once-daily (QD) trizivir (TZV) and tenofovir (TDF) in antiretroviral naive subjects (COL40263). Presented at: The 45th ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC.
poster 35 Elion R, Ha B, DeJesus E, Cohen C, et al. Selection of HIV reverse transcriptase (RT) thymidine analogue mutations (TAMS) rather then K65R is the preferred route of resistance seen in patients with virologic failure (VF) for once-daily (QD) trizivir (TZV) and tenofovir (TDF). Presented at: The 45th ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC.
poster3 Horne R, Clotet B, Cohen CJ, et al. Treatment-experienced patient perceptions of self-injectable therapy. Presented at: The 10th European AIDS Conference/EACS; November 17-20, 2005; Dublin, Ireland.
 dsfdsf Cohen CJ. Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations. The AIDS Reader. 15(10):528-532. Oct 2005. A Cliggott Publication. PMID: 16265768.
abstract 36 Colson A, Hellinger J, Cohen CJ, et al. The StARS study: Once daily atazanavir, low-dose ritonavir and saquinavir – 24 week efficacy and safety results. Presented at: The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 21-27, 2005; Rio de Janeiro, Brazil.
abstract5 Cohen CJ, Colson A, Morris A, et al. The FOTO study 48 week results: viral suppression can be maintained when antiretrovirals are taken five consecutive days on, and two days off each week. Presented at: The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 21-27, 2005; Rio de Janeiro, Brazil.
poster6 Powderly W, Cohen CJ, Gallant J, et al. Similar incidence of osteopenia and osteoporosis in ART-naïve patients treated with tenovir DF or stavudine in combination with lamivudine and efavirenz over 144 weeks. Presented at: The 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA.
article 36 Cohen CJ. Comparing a treatment interruption with or without interleukin-2 in delaying a falling CD4+ cell count. The Body Covers: 12th Conference on Retroviruses and Opportunistic Infections; February 25, 2005; Boston, MA.
article 37 Cohen CJ. Multi-national trial confirms superiority of 3-drug regimen containing efavirenz for the treatment naïve. The Body Covers: 12th Conference on Retroviruses and Opportunistic Infections; February 20, 2005; Boston, MA.
Not Available Online DeJesus E, Elion R, Cohen CJ, et al. Week 24 analysis of once-daily (QD) trizivir (TZV) and tenofovir DF (TDF) in antiretroviral naïve subjects (COL40263). Presented at: The 44th Annual ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC.
abstract 40poster 40 Cohen CJ, Schneider S, Dretler R, et al. Efficacy and safety of switching HIV-1 infected subjects from a protease inhibitor to an efavirenz-based regimen: VEST-QD Week 24 interim results. Presented at: The 44th Annual ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC.
abstract 41 Lalezari JP, Bellos N, Richmond G,Sathasivam K, Cohen CJ, et al. Final analysis of T1249-102: T-1249 retains potent short-term antiviral activity in patients who have failed a regimen containing enfuviritide. Presented at: The 44th Annual ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC.
poster 45 Ward D, Cohen CJ, Keiser P, et al. Efficacy and safety of efavirenz (EFV), lamivudine (3TC), didanosine-EC (DDI-EC), as a once daily regimen for treatment-naïve HIV patients: 48 week results from the DART I trial. Proceedings of The XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
abstract 46 Cohen CJ, Morris AB, Colson A, et al. The FOTO study: A pilot study of short-cycle treatment interruption, taking antiretroviral medications for five days on, two days off (FOTO) for those with viral load suppression. Presented at: The XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
abstract 47 Morris AB, Juethner SN, Hellinger J, Cohen CJ. The metabolic abnormalities and cardiovascular risk factors in HIV-infected hispanics in western MA. Proceedings of The XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
 Not Available Online Elion R, Cohen CJ, DeJesus E, et al. Resistance and efficacy of once-daily trizivir and tenofovir DF in antiretroviral naïve subjects. Presented at: The Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA.
abstract 50 DeJesus E, Cohen CJ, Sax P, et al. Improvement in quality of life with once-daily didanosine-ED (DDI-ED), lamivudine (3TC), and efavirenz (EFV): 24 week interim results from the DART I Trial. Presented at: The 41st Annual Meeting of Infectious Disease Society of America; October 10, 2003; San Diego, CA.
Not Available Online DeJesus E, Cohen CJ, Sax P, et al. Efficacy and safety of didanosine-EC (DDI-EC), lamivudine (3TC), and efavirenz (EFV) as a once-daily regimen for treatment-naïve HIV patients: 24-week interim results from the DART I trial. Presented at: The 41st Annual Meeting of Infectious Disease Society of America; October 10, 2003; San Diego, CA.
abstract 50 Hellinger J, Cohen CJ, Morris AB, et al. A pilot study of saquinavir-SGC (SQV) and lopinavir/ritonavir (LPV/R) twice daily in protease Iinhibitor (PI)-naïve HIV-positive individuals: Protease inhibitor concentrations and week 24 results. Presented at: The 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France.
abstract 51 Cohen CJ, Clumeck N, Molina JM, et al. Impact of enfuvirtide on health-related quality of life. Proceedings of The 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France.
abstract 52 Hellinger JA, Glesby M, Stein A, Morris AJ, Taial A, Tuscher SA, Greenough T, Becker M,Chua A, Cohen CJ, et al. Evaluation of oral pancrelipase (ultrase MT-20) for the symptomatic control of nelfinavir-associated diarrhea. Presented at: The XIV International AIDS Conference; July 2002; Barcelona, Spain.
abstract 53 Gordon DM, Foy K, Morris AB, Hellinger JA, de Caprariis PJ, Jackson-Pope L, Cohen CJ, et al. Successful management of gastrointestinal (GI) adverse events (AEs) in a prospective trial of ritonavir boosted saquinavir/lopinavir in heavily PI experienced patients. Presented at: The XIV International AIDS Conference; July 2002; Barcelona, Spain.
abstract7 Hellinger J, Cohen CJ, Morris AB, et al. A pilot study of saquinavir-SGC (fortovase,SQV) 1000mg and lopinavir/ritonavir (LPV/R) twice daily in protease inhibitor naïve (PIN) HIV-positive individuals. Proceedings of The XIV International AIDS Conference; July, 2002; Barcelona, Spain.
abstract 54 Sax PE, Islam R, Losina E, Weinstein M, Cohen CJ, et al. Should resistance testing be done in antiretroviral-naïve patients? A cost-effectiveness analysis. Proceedings of The XIV International AIDS Conference; July, 2002. Barcelona, Spain.
 Not Available Online Hellinger JA, Morris AB, Piscitelli S, Gordon D, Foy K, Jackson-Pope L, Cordeir D, Peeters M, Hoetelmans R, de Caprariis PJ and Cohen CJ. Pilot study of saquinavir-SGC (fortovase, SQV) 1000mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor-experienced HIV+ individuals: Dose escalation and combined normalized inhibitory quotient (cNIQ). Presented at: The 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington.
Not Available Online Cameron DW, Angel JB, Ryan J, Jiang P, Rode R, Farthing C, Cohen CJ, et al. Durability of ritonavir (RTV) plus saquinavir (SQV) dual protease inhibitor therapy in HIV infection: 5-year follow-up. Presented at:The 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington.
abstract8 Ross L, Liao Q, Henry K, Cohen CJ, et al. Choice of co-nucleoside analog in d4T-treated subjects may influence the pattern of thymidine analog mutations (TAMs) and multi-nucleoside resistance mutations (MNRs). Presented at: The 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington.
Not Available Online Cohen CJ, Shen Y, Rode R, et al. Effect of nucleoside (NRTI) intensification on prevalence of morphologic abnormalities (MoAs) at year 5 of ritonavir (RTV) plus saquinavir (SQV) therapy in an HIV-infected cohort. Presented at: The 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington.
Not Available Online Murphy L, Katlama C, Belsey EM, Berzins B, Montaner JSG, Harris M, Pollard R, Hellinger JA, Cohen CJ, et al. Antiretroviral activity, toxicity, and pharmacokinetics in patients treated with efavirenz, didanosine, and stavudine with and without hydroxyurea: 48 week results, the 3D study. Presented at: The 8th European Conference on Clinical Aspects and Treatment of HIV Infection; October 28-31, 2001; Athens, Greece.
Not Available Online Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GS, Cohen CJ, et al. Primary HIV infection (PHI): Comparing treatment strategies. Presented at: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Illinois.
Not Available Online Hellinger JA, Cohen CJ, Squires K, et al. Antiretroviral activity, toxicity, and pharmacokinetics in patients treated with efavirenz, didanosine, and stavudine with and without hydroxyurea: 48 week results, the 3rd study. Presented at: 1st IAS Conference on HIV Pathogenesis and Treatment; June, 2001; Buenos Aires.
Not Available Online Cohen CJ, Ryan J, Cameron DW, et al. Effect of nucleoside intensification on prevalence of body composition abnormalities at week 144 of ritonavir plus saquinavir therapy in HIV-infection. Proceedings of The 2nd International Workshop on Lipodystrophy and Adverse Effect; October, 2000; Toronto, Canada.
Not Available Online Losina E, Weinstein MC, Goldie SJ, Paltiel AD, Seage GR, Walensky RP, Cohen CJ, et al. Sources of variation in model-based life expectancy: Portraying treatment efficacy in HIV disease. Proceedings of The 22nd Annual Meeting for the Society of Medical Decision Making; September 24-27, 2000; Cincinnati, Ohio.
abstract 55 Verbiest W, Peeters M, Hertogs K, Schel P, Bloor S, Rinehart A, Graham N, Cohen CJ, et al. Virtual phenotype is concordant with actual phenotype: A retrospective analysis of data from VIRA3001. Proceedings of The 40th ICAAC; September 17-20, 2000; Toronto, Canada.
abstract 56 Cohen CJ, Sension M, Macko J, et al. Response to highly active antiretroviral therapy (HAART) following prior treatment with saquinavir soft gel capsules. Proceedings of The 40th ICAAC; September 17-20, 2000; Toronto, Canada.
abstract9 Freedberg KA, Losina E, Weinstein MC, Goldie SJ, Paltiel A, Cohen CJ, et al. Strategies for HIV care: Clinical impact and cost-effectiveness. Proceedings of The XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa.
abstract 57 Cohen CJ, Kessler H, Hunt S, et al. Phenotypic resistance testing significantly improves response to therapy: Final analysis of a randomized trial (VIRA3001). Proceedings of The 4th International Workshop on HIV Drug Resistance and Treatment Strategies; June 12-16, 2000; Sitges, Spain.
Not Available Online Goldie SJ, Paltiel Ad, Weinstein MC, Losina E, Seage GR, Cohen CJ, et al. Cost-effectiveness of interventions to improve adherence to highly-active antiretroviral therapy (HAART) in HIV-infected patients. Proceedings of The 23rd Annual Meeting of the Society of General Internal Medicine; May 4-6, 2000; Boston, MA.
Not Available Online Cameron DW, Xu Y, Rode R, Cohen CJ, et al. Three-year follow-up and conditional outcomes survival analysis of ritonavir (RTV) plus saquinavir (SQV) therapy in HIV infection. Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, CA.
Not Available Online Lalezari J, Beal J, Ruane P, Cohen CJ, et al. Low-dose subcutaneous (SC) IL-2 in combination with HAART therapy induces significant increases in NK cells and naïve t-cells in patients with <300 CD4+ t-cells/mm3: Results of a randomized controlled trial MA-9801. Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, CA.
Not Available Online Cohen CJ, Hunt S, Sension M, et al. Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA3001). Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, CA.
Not Available Online Cohen CJ. Commentary on Pneumocystis Pneumonia in a Prepaid Care System Caring for a Medicaid-Covered Population with AIDS. Journal of Ambulatory Care Management. 19(1):42-44. Jan 1996. PMID: 10154368.
 dfdf Cohen CJ, Shevitz A, Mayer K. Expanding Access to Investigational New Therapies. Primary Care. 19(1):87-96. Mar 1992. PMID 1594704.
Capture Freedberg KA, Tosteson ANA, Cohen CJ, et al. Inhaled Pentamidine and Prevention of Pneumocystis Pneumonia. New England Journal of Medicine. 325(10):735. Sep 5, 1991 (Letter).